ClinicalTrials.gg
CompletedNCT02648334DCB-SFAUpdated Aug 9, 2024

Randomized Comparison of DCB for the Treatment of Superficial Femoral and Popliteal Peripheral Artery Disease

An interventional study of IN.PACT drug coated balloon and Lutonix drug coated balloon in Angioplasty, Balloon, Catheterization, Peripheral and Popliteal Artery, sponsored by Seung-Whan Lee, M.D., Ph.D.. Completed at 14 sites in Korea, Republic of. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2024-08-09.

Sponsored by Seung-Whan Lee, M.D., Ph.D. · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
443
Allocation
Randomized
Ages
19 Years and older
Sex
All
01

Study summary

This study evaluates the safety and effectiveness Percutaneous Transluminal Angioplasty(PTA) using Drug-Coated Balloons for the treatment of Superficial Femoral and popliteal peripheral Artery disease.

02

Conditions studied

  • Angioplasty, Balloon
  • Catheterization, Peripheral
  • Popliteal Artery
  • Femoral Artery

Keywords

  • Drug-Coated Balloon
  • Superficial Femoral artery
  • popliteal peripheral Artery
03

In context

Lead sponsor

Seung-Whan Lee, M.D., Ph.D. is the lead sponsor of 5 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 19 and above
  • Subject with claudication or critical limb ischemia(Rutherford classification level 2\~5)
  • Subject with total occlusion or stenosis ≥70%(de novo, restenosis)
  • Vessel diameter 4\~6mm
  • Success to guide wire pass
  • Patients who don't have known or allergy for dual-
  • Willing and able to provide informed written consent

Exclusion criteria

Exclusion Criteria:

  • Acute stage
  • Acute thrombosis in target limb or target vessel
  • Failure to guide wire pass
  • Distal outflow
  • Lesion with poor inflow
  • ≤ 2 years
  • Allergic to paclitaxel
  • Pregnant or breast feeding woman or disagree with or having children
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
443 participants (actual)

Study arms

  • Active comparator
    IN.PACT drug coated balloon

    IN.PACT drug coated balloon

    Device: IN.PACT drug coated balloon

  • Experimental
    Lutonix drug coated balloon

    Lutonix drug coated balloon

    Device: Lutonix drug coated balloon

Interventions

  • DeviceIN.PACT drug coated balloon
  • DeviceLutonix drug coated balloon
06

What researchers measure

Primary outcomes

  1. the event rate of composite event

    all cause death, revascularization due to amputation or clinical evidence

    Time frame: 1 year

Secondary outcomes

  1. all cause death

    Time frame: 2 years

  2. cardiac death

    Time frame: 2 years

  3. myocardial infarction

    Time frame: 2 years

  4. stroke

    Time frame: 2 years

  5. amputation of target limb

    Time frame: 2 years

  6. target lesion revascularization

    Time frame: 2 years

  7. The change of Rutherford classification

    Time frame: 2 years

  8. The change of ABI(ankle-brachial index) score

    Time frame: 2 years

  9. MACE

    major adverse cardiac event(death, myocardial infarction, stroke)

    Time frame: 2 years

  10. thrombosis

    Time frame: 2 years

07

Study locations

14 sites
  • Hallym University Sacred Heart Hospital
    Anyang, Korea, Republic of
  • Gyeongsang National University Changwon Hospital
    Changwon, Korea, Republic of
  • Kangwon National University Hospital
    Chuncheon, Korea, Republic of
  • Chungnam National University Hospital
    Daejeon, Korea, Republic of
  • Myongji Hospital
    Goyang-si, Korea, Republic of
  • Seoul national university Bundang hospital
    Gyeonggi-do, Korea, Republic of
  • Jesushospital
    Jeonju, Korea, Republic of
  • Dong-A Medical Center
    Pusan, Korea, Republic of
  • Inje University Pusan Paik Hospital
    Pusan, Korea, Republic of
  • Veterans Hospital
    Pusan, Korea, Republic of
  • Chungnam National University Sejong Hospital
    Sejong, Korea, Republic of
  • Asan Medical Center
    Seoul, Korea, Republic of
  • Kangbuk Samsung Medical Center
    Seoul, Korea, Republic of
  • Veterans Hospital Service Medical Center
    Seoul, Korea, Republic of
08

References and documents

Individual participant data

Plan to share: No — This is not publicly funded trial.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2016 to primary completion in Jan 2023, 74 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 5, 2016
First posted
Jan 7, 2016
StartActual
Nov 10, 2016
Primary completionActual
Jan 19, 2023
CompletionActual
Aug 7, 2024
Last update
Aug 9, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 9, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02648334
Lead sponsor
Seung-Whan Lee, M.D., Ph.D.
Responsible party
Seung-Whan Lee, M.D., Ph.D. (Division of Cardiology, Asan Medical Center) — Sponsor-investigator
First posted
Jan 7, 2016
Start date
Nov 10, 2016
Primary completion
Jan 19, 2023
Completion
Aug 7, 2024
Last update
Aug 9, 2024

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion